Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors
How Is the Oral Vaccine Market Growth Forecast from 2025 to 2029?
The oral vaccine market size has grown rapidly in recent years. It will grow from $3.59 billion in 2024 to $3.95 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing investments in vaccine research and development, favorable regulatory support for oral vaccine trials, rise in global travel and tourism, need for mass immunization during outbreaks, and the expansion of cold chain infrastructure.
The oral vaccine market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to rising global burden of infectious diseases, increasing demand for needle-free vaccine administration, higher acceptance rates among pediatric patients, improved patient compliance, and growth in immunization programs by governments. Major trends in the forecast period include the emergence of new oral vaccine technologies, technological advancements in oral drug delivery, collaborations between public and private sectors, development of oral vaccines for non-traditional diseases, and innovations in encapsulation and formulation techniques.
Claim your free report sample now:
What Are the Key Growth Factors Supporting the Oral Vaccine Market Expansion?
The rising prevalence of infectious diseases is expected to propel the growth of the oral vaccine market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can be transmitted between individuals or through the environment. Infectious diseases are rising due to increasing global travel, which enables the rapid movement of people and pathogens across borders, accelerating the spread of infections worldwide. Oral vaccines are beneficial for infectious diseases as they stimulate mucosal immunity in the gut, which is a primary entry point for many pathogens, thereby offering effective protection at the site of infection. For instance, in May 2025, according to the Health Security Agency, a UK-based government department, in England, the number of reported tuberculosis (TB) cases in 2023 showed an 11.0% increase compared to 2022. Therefore, the rising prevalence of infectious diseases is driving the growth of the oral vaccine market.
What Segments Are Covered in the Oral Vaccine Market Report?
The oral vaccine market covered in this report is segmented
1) By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Other Vaccine Types
2) By Application: Polio, Tuberculosis, Rabies, Influenza, Cholera, Other Applications
3) By End-User: Hospital , Clinics, Government Organization, Other End-Users
Subsegments:
1) By Live Attenuated Vaccines: Oral Polio Vaccine (OPV), Rotavirus Vaccine, Oral Typhoid Vaccine, Oral Cholera Vaccine
2) By Inactivated Vaccines: Inactivated Polio Vaccine (IPV), Inactivated Cholera Vaccine, Inactivated Hepatitis A Vaccine
3) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Vaccines, Conjugate Vaccines
4) By Other Vaccine Types: DNA Vaccines, RNA Vaccines, Virus-Like Particle (VLP) Vaccines, Recombinant Vector Vaccines
What Are the Key Trends Shaping the Oral Vaccine Market?
Major companies operating in the oral vaccine market are focusing on developing innovative products, such as second-generation oral pill vaccines, to enhance immune response and ease of administration. A second-generation pill-based oral vaccine is designed to improve immunogenicity, broaden protection, and streamline mass immunization without the need for needles or cold-chain storage. For instance, in March 2025, Vaxart Inc., a U.S.-based biotechnology company, announced the initiation of a Phase 1 clinical trial for its second-generation oral norovirus vaccine delivered in pill formulation. This trial will evaluate improved immune responses and safety features of the updated constructs, aiming to address the ongoing global need for accessible and effective norovirus immunization. The pill format removes barriers associated with injectable vaccines and supports rapid, large-scale distribution, particularly during outbreaks.
Who Are the Key Players Driving the Oral Vaccine Market?
Major companies operating in the oral vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Sinovac Biotech Ltd., Panacea Biotec Ltd., Emergent BioSolutions Inc., Zydus Lifesciences, Serum Institute of India Pvt. Ltd., Bharat Biotech Ltd., Adimmune, Haffkine Biopharmaceutical Co. Ltd., Changchun BCHT Biotechnology Co., BIBCOL, Medigen Vaccine Biologics Corp., BlueWillow Biologics Inc., BioNet Asia Co. Ltd., and Innovax.
Get the full oral vaccine market report here:
How Does Oral Vaccine Market Growth Vary Across Major Regions?
North America was the largest region in the oral vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment